NCT02730624View on ClinicalTrials.gov

Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

January 31, 2017

Conditions
Early Phase of Severe Sepsis and Septic Shock
Interventions
DRUG

Piperacillin-tazobactam

4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration

Trial Locations (1)

90110

Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai

All Listed Sponsors
collaborator

Prince of Songkla University

OTHER

lead

Sutep Jaruratanasirikul

OTHER

NCT02730624 - Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock | Biotech Hunter | Biotech Hunter